Probi AB (PROB):企業の財務・戦略的SWOT分析

【英語タイトル】Probi AB (PROB) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C2734)・商品コード:DATA904C2734
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:55
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Probi AB (PROB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Probi AB (Probi) is a biotechnology company develops, produces and markets probiotics. The company offers licenses for its technology and sells finished products in bulk. It focuses on products for the improvement of gastrointestinal health and immune system. It distributes its products to leading food, health-product and pharmaceutical companies in the functional food and consumer healthcare segments. Probi markets its products through four different platforms: Probi Premium, Probi Select, Probi LiveBac and Probi Bio-tract. The company has operational presence in Sweden, Rest of Europe, North America and Rest of world. Probi is headquartered in Lund, Sweden.

Probi AB Key Recent Developments

Jul 19,2018: Probi announces resignation of Jorn Andreas as CFO
Apr 11,2018: Probi enters the bone health area – a new area for probiotics
Mar 14,2018: Probi Appoints Ole Sogaard Andersen As Interim CEO
Feb 06,2018: Probi’s largest clinical trial confirms the immune enhancing impact of Probi Defendum and sheds new light on the mechanism
Jan 25,2018: Probi: Q4 – 2017 Year-End Report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Probi AB – Key Facts 6
Probi AB – Key Employees 7
Probi AB – Key Employee Biographies 8
Probi AB – Major Products and Services 9
Probi AB – History 10
Probi AB – Company Statement 13
Probi AB – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
Probi AB – Business Description 17
Business Segment: Consumer Healthcare Segment 17
Overview 17
Performance 17
Business Segment: Functional Food Segment 17
Overview 17
Performance 17
Geographical Segment: North America 17
Performance 17
Geographical Segment: Rest of Europe 17
Performance 17
Geographical Segment: Rest of the World 18
Performance 18
Geographical Segment: Sweden 18
Performance 18
Probi AB – SWOT Analysis 19
SWOT Analysis – Overview 19
Probi AB – Strengths 19
Probi AB – Weaknesses 20
Probi AB – Opportunities 21
Probi AB – Threats 22
Probi AB – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Probi AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Probi AB, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Apr 11, 2018: Probi enters the bone health area – a new area for probiotics 34
Feb 06, 2018: Probi’s largest clinical trial confirms the immune enhancing impact of Probi Defendum and sheds new light on the mechanism 35
Jan 25, 2018: Probi: Q4 – 2017 Year-End Report 36
Oct 25, 2017: Probi: Interim report Q1-Q3 2017 41
Sep 11, 2017: New clinical study shows that Probi’s probiotics support the immune system and may delay the onset of gluten intolerance in children 45
May 04, 2017: Probi continues on its successful growth path 46
Feb 14, 2017: Probi appoints Jorn Andreas as new CFO 49
Jan 10, 2017: Probi – Strong Growth in net Sales and Operating Profit in the Fourth Quarter 50
Section 6 – Appendix 51
Methodology 51
Ratio Definitions 51
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Probi AB, Key Facts 6
Probi AB, Key Employees 7
Probi AB, Key Employee Biographies 8
Probi AB, Major Products and Services 9
Probi AB, History 10
Probi AB, Subsidiaries 15
Probi AB, Key Competitors 23
Probi AB, Ratios based on current share price 24
Probi AB, Annual Ratios 25
Probi AB, Annual Ratios (Cont...1) 26
Probi AB, Annual Ratios (Cont...2) 27
Probi AB, Interim Ratios 29
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Probi AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Probi AB, Recent Deals Summary 33
Currency Codes 51
Capital Market Ratios 51
Equity Ratios 52
Profitability Ratios 52
Cost Ratios 53
Liquidity Ratios 53
Leverage Ratios 54
Efficiency Ratios 54

List of Figures
Probi AB, Performance Chart (2013 - 2017) 28
Probi AB, Ratio Charts 30
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

★調査レポート[Probi AB (PROB):企業の財務・戦略的SWOT分析] (コード:DATA904C2734)販売に関する免責事項を必ずご確認ください。
★調査レポート[Probi AB (PROB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆